11/7
08:36 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $151.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $151.00 price target on the stock.
11/7
08:36 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
11/7
02:19 am
prax
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... [Yahoo! Finance]
11/6
05:00 pm
prax
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
Medium
Report
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
11/6
07:30 am
prax
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Low
Report
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
11/1
08:00 am
prax
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
Low
Report
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
10/31
02:35 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $143.00 to $163.00. They now have an "outperform" rating on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $143.00 to $163.00. They now have an "outperform" rating on the stock.
10/21
10:17 am
prax
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate [Yahoo! Finance]
10/4
10:24 am
prax
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last? [Yahoo! Finance]
9/26
08:00 am
prax
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
Low
Report
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
9/10
08:01 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Low
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
9/5
08:00 am
prax
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Medium
Report
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
9/4
11:03 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $143.00 price target on the stock, up previously from $134.00.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $143.00 price target on the stock, up previously from $134.00.
9/4
08:00 am
prax
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Medium
Report
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
9/3
02:08 pm
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
9/3
11:09 am
prax
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $145.00 price target on the stock.
Medium
Report
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $145.00 price target on the stock.
9/3
07:30 am
prax
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Medium
Report
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
9/2
05:04 pm
prax
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 [Yahoo! Finance]
9/2
05:00 pm
prax
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
Medium
Report
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024